CUREVAC
LIVE

Serial Number

88602178

Owner

CUREVAC SE

Attorney

Jennifer Fraser

Filing Date

Sep 3, 2019

Add to watchlist:

No watchlists yet
View on USPTO

CUREVAC Trademark

Serial Number: 88602178 • Registration: 6318156

CUREVAC is a trademark filed by CUREVAC SE on September 3, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

CUREVAC SE (14 trademarks)

FRIEDRICH-MIESCHER-STR. 15
TÜBINGEN 72076 , DE

Entity Type: 94

CureVac AG

Tübingen 72076 , DE

Entity Type: 99

Trademark Details

Filing Date

September 3, 2019

Registration Date

April 13, 2021

Published for Opposition

January 26, 2021

Goods & Services

Chemical reagents and biomolecules, in particular biological macromolecules, for industrial or scientific purposes; Reagents for research purposes

Medical and veterinary services, in particular for therapeutic and prophylactic treatment of cancer diseases, infectious diseases, autoimmune diseases or allergies; Medical and veterinary services for treating of hereditary disorders; Medical and veterinary services for protein or enzyme supplement therapy for therapeutic or prophylactic treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases and for treatment of endocrinological or metabolic disorders

Chemical preparations for medical use, namely, for therapeutic and prophylactic treatment of neurological, neuromuscular, neurodegenerative, infectious and cardiovascular diseases, of autoimmune diseases and cancer diseases, of tumours, of allergies, of metabolic diseases, of heritable genetic diseases, and for therapies replacing proteins or enzymes; pharmaceutical preparations, namely, immunostimulants, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, vaccines, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, adjuvant immunostimulants; pharmaceuticals and medicaments containing biological macromolecules, in particular for human or veterinary purposes for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for the treatment of infectious diseases, autoimmune diseases and tumours, for treatment of cancers, for treatment of metabolic diseases and for treatment of heritable genetic diseases and for protein or enzyme replacement therapy; gene therapy products, namely, nucleic acid macromolecules for in vivo expression for human or veterinary medical use; Dietetic substances adapted for medical use, in particular substances for food supplements, namely, dietary food supplements; Peptide carrier molecules for association with a biological macromolecule, for medical use, namely, for use in facilitating delivery of a wide range of medicinal substances; Peptidic carrier molecule for preparing a pharmaceutical composition, namely, for medical use as a protein delivery preparation to expedite or improve delivery of a therapeutic macromolecule or prophylactic biological marcomolecule; Peptide carrier molecule, sold in combination with a biological macromolecule for preparing a pharmaceutical composition, namely, for medical use as a protein delivery preparation to expedite or improve delivery of a therapeutic drug or prophylactic drug

Scientific and technological services and research, in particular scientific research for identification, testing and characterisation of biological macromolecules; medical testing services, namely, pre-clinical and clinical testing of macromolecules; scientific research in the nature of discovery of biological macromolecules; Laboratory services, related to custom manufacturing of pharmaceutical ingredients, for identification, testing and characterisation of biological macromolecules

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 13, 2026 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 8, 2023 ASGN
CORRECTION UNDER SECTION 7 - PROCESSED
Sep 30, 2021 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 30, 2021 APRE
TEAS SECTION 7 REQUEST RECEIVED
Apr 30, 2021 ES7R
REGISTERED-PRINCIPAL REGISTER
Apr 13, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 26, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jan 26, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 6, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 17, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 17, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 17, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 17, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 17, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 16, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 16, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 15, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 30, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jun 30, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jun 30, 2020 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 16, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 16, 2020 CRFA
ASSIGNED TO LIE
Jun 15, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 4, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 9, 2019 GNRN
NON-FINAL ACTION E-MAILED
Dec 9, 2019 GNRT
NON-FINAL ACTION WRITTEN
Dec 9, 2019 CNRT
ASSIGNED TO EXAMINER
Dec 5, 2019 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 14, 2019 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 13, 2019 NWOS
NEW APPLICATION ENTERED
Sep 6, 2019 NWAP